Epigenetic Targeting of Clear Cell Renal Cell Carcinoma

Project: Research project

Project Details

Description

Going forward, three critical questions need to be answered, that are addressed by our proposal: 1. What is the effect of redistribution and loss of 5-hmC on individual pathways in ccRCC tumors? 2. What is the functional consequence of loss of 5-hmC in vivo, and can it be rescued by AA? 3. What are the biomarkers that predict a combinatorial response of AA with standard of care Pazopanib in the first line setting for metastatic/ unresectable ccRCC. Aim 1: Determine genome wide alterations in hydroxymethylation (5-hmC) in ccRCC and correlate them with transcriptomic alterations. Aim 2: Determine the functional significance of loss of 5-hmC in ccRCC carcinogenesis in vivo, and utility of AA in inhibiting ccRCC carcinogenesis. Aim 3: Determine biomarkers to predict response to combination of high-dose AA with standard of care Pazopanib in the first line setting for metastatic/ unresectable ccRCC
StatusActive
Effective start/end date1/1/2112/31/24

Funding

  • American Cancer Society (RSG-20-137-01-TBG)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.